Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | APLNR | P35414 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823357 | 0.85 | GABRA1 (0.41) | NR1H4APLNRKMT2AALOX12ALDH1A1 | |
| SCHEMBL823371 | 0.84 | NR1I3 (0.45) | NR1I3APLNRKMT2AGAAMEN1 | |
| SCHEMBL823394 | 0.79 | NR1I3 (0.49) | NR1I3NR1H4RNASEH1ALDH1A1KDM4E | |
| SCHEMBL823398 | 0.78 | SMN1; SMN2 (0.41) | NR1I3NR1H4RNASEH1ALDH1A1GAA | |
| SCHEMBL823354 | 0.76 | HPGD (0.46) | KMT2AALDH1A1GAAKDM4ETSHR | |
| SCHEMBL823388 | 0.73 | NPC1 (0.49) | NR1H4KMT2AALDH1A1GAAKDM4E | |
| SCHEMBL823373 | 0.73 | SMN1; SMN2 (0.48) | NR1H4ALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL823391 | 0.70 | TP53 (0.43) | ALDH1A1CASP1CASP7HSD17B10HPGD | |
| SCHEMBL12953161 | 0.70 | HPGD (0.32) | KMT2AALDH1A1GAAKDM4EGLA | |
| SCHEMBL1220967 | 0.70 | SLC2A1 (0.44) | GAAKDM4EHPGDTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| EP-2759544-A1 | Compounds having antiviral properties | Avexa Limited (AU) | 2014-07-30 | — | — | EP | disclosed |
| EP-2212324-B1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LTD (AU) | 2014-03-26 | — | — | EP | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-8207334-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-06-26 | — | — | US | disclosed |
| EP-2114903-B1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2011-01-26 | — | — | EP | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| EP-2269992-A1 | Bicyclic pyrimidinones for the treatment of viral infections | Avexa Limited (AU) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269992-A1 | Bicyclic pyrimidinones for the treatment of viral infections | Avexa Limited (AU) | 2011-01-05 | — | — | EP | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| WO-2008077188-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | NR1I3 958/4885NR1H4 730/4885APLNR 3416/4885 |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | TPMT, TYMP, DPYD | NR1I3 958/4885NR1H4 730/4885APLNR 3416/4885 |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | NR1I3 958/4885NR1H4 730/4885APLNR 3416/4885 |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | NR1I3 1131/4885NR1H4 395/4885APLNR 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.